RU2014111179A - КОНЪЮГАТЫ ИНТЕРФЕРОНА λ1 И ПОЛИЭТИЛЕНГЛИКОЛЯ - Google Patents
КОНЪЮГАТЫ ИНТЕРФЕРОНА λ1 И ПОЛИЭТИЛЕНГЛИКОЛЯ Download PDFInfo
- Publication number
- RU2014111179A RU2014111179A RU2014111179/10A RU2014111179A RU2014111179A RU 2014111179 A RU2014111179 A RU 2014111179A RU 2014111179/10 A RU2014111179/10 A RU 2014111179/10A RU 2014111179 A RU2014111179 A RU 2014111179A RU 2014111179 A RU2014111179 A RU 2014111179A
- Authority
- RU
- Russia
- Prior art keywords
- interferon
- conjugate
- polyethylene glycol
- conjugate according
- alkyl
- Prior art date
Links
- 102100020990 Interferon lambda-1 Human genes 0.000 title claims abstract 18
- 101710099623 Interferon lambda-1 Proteins 0.000 title claims abstract 18
- 239000002202 Polyethylene glycol Substances 0.000 title claims abstract 10
- 229920001223 polyethylene glycol Polymers 0.000 title claims abstract 10
- 125000000217 alkyl group Chemical group 0.000 claims abstract 8
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 5
- -1 4-nitrophenoxycarbonyl Chemical group 0.000 claims abstract 4
- 150000003839 salts Chemical class 0.000 claims abstract 4
- 208000005176 Hepatitis C Diseases 0.000 claims abstract 3
- 230000021615 conjugation Effects 0.000 claims abstract 3
- 208000002672 hepatitis B Diseases 0.000 claims abstract 3
- 230000014759 maintenance of location Effects 0.000 claims abstract 3
- 210000002966 serum Anatomy 0.000 claims abstract 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims abstract 2
- 239000003937 drug carrier Substances 0.000 claims abstract 2
- 125000003827 glycol group Chemical group 0.000 claims abstract 2
- 238000004519 manufacturing process Methods 0.000 claims abstract 2
- 229930182817 methionine Natural products 0.000 claims abstract 2
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 claims abstract 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract 2
- 238000000034 method Methods 0.000 claims 12
- 208000036142 Viral infection Diseases 0.000 claims 4
- 230000009385 viral infection Effects 0.000 claims 4
- 229960004556 tenofovir Drugs 0.000 claims 3
- VCMJCVGFSROFHV-WZGZYPNHSA-N tenofovir disoproxil fumarate Chemical compound OC(=O)\C=C\C(O)=O.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VCMJCVGFSROFHV-WZGZYPNHSA-N 0.000 claims 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 229960000329 ribavirin Drugs 0.000 claims 2
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 claims 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 2
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 230000037396 body weight Effects 0.000 claims 1
- 230000007882 cirrhosis Effects 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 239000002777 nucleoside Substances 0.000 claims 1
- 150000003833 nucleoside derivatives Chemical class 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 claims 1
- NHKZSTHOYNWEEZ-AFCXAGJDSA-N taribavirin Chemical compound N1=C(C(=N)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NHKZSTHOYNWEEZ-AFCXAGJDSA-N 0.000 claims 1
- 229950006081 taribavirin Drugs 0.000 claims 1
- 102000014150 Interferons Human genes 0.000 abstract 2
- 108010050904 Interferons Proteins 0.000 abstract 2
- 229940079322 interferon Drugs 0.000 abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| VN201102222 | 2011-08-25 | ||
| VNVN1-2011-02222 | 2011-08-25 | ||
| PCT/US2012/027317 WO2013028233A1 (en) | 2011-08-25 | 2012-03-01 | Peg-interferon lambda 1 conjugates |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2014111179A true RU2014111179A (ru) | 2015-09-27 |
Family
ID=47746747
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2014111179/10A RU2014111179A (ru) | 2011-08-25 | 2012-03-01 | КОНЪЮГАТЫ ИНТЕРФЕРОНА λ1 И ПОЛИЭТИЛЕНГЛИКОЛЯ |
Country Status (9)
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3416675T3 (pl) * | 2016-02-19 | 2021-10-11 | Eiger Biopharmaceuticals, Inc. | Leczenie zakażenia wirusem zapalenia wątroby typu delta za pomocą interferonu lambda |
| ES3015227T3 (en) | 2017-03-16 | 2025-04-30 | Evangelos Andreakos | Use of lambda interferons in the treatment of an obesity-related disorder, atherosclerosis or a coagulation disorder |
| RU2678332C1 (ru) * | 2017-09-08 | 2019-01-28 | Общество с ограниченной ответственностью "Саентифик Фьючер Менеджмент" (ООО "СФМ") | Пегилированный интерферон лямбда, обладающий высокой биодоступностью при пероральном применении, и способ его получения |
| CN112245570A (zh) | 2019-07-22 | 2021-01-22 | 厦门特宝生物工程股份有限公司 | 一种基于干扰素的疾病治疗方法 |
| KR20230157947A (ko) | 2021-01-21 | 2023-11-17 | 샤먼 아모이탑 바이오테크 컴퍼니 리미티드 | 암 재발 방지를 위한 방법 및 약제학적 조합 |
| KR20230157313A (ko) | 2021-01-21 | 2023-11-16 | 샤먼 아모이탑 바이오테크 컴퍼니 리미티드 | 인터페론-기반 암 치료 방법 및 약제학적 조합 |
| WO2024121424A1 (en) | 2022-12-09 | 2024-06-13 | Daniel Zagury | Composite aids vaccine generating anti-hiv specific neutralizing antibodies and/or anti-hiv cytotoxic t cells |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5382657A (en) * | 1992-08-26 | 1995-01-17 | Hoffmann-La Roche Inc. | Peg-interferon conjugates |
| CN1176137C (zh) * | 2002-01-15 | 2004-11-17 | 泛亚生物技术有限公司 | 多臂树杈型功能化聚乙二醇制备方法及它在药物中的应用 |
| CN1927388B (zh) * | 2004-09-10 | 2011-02-02 | 北京金迪克生物技术研究所 | 含有人干扰素的药物组合物 |
| WO2006133089A2 (en) * | 2005-06-03 | 2006-12-14 | Ambrx, Inc. | Improved human interferon molecules and their uses |
| DK1931704T3 (da) * | 2005-10-04 | 2011-03-14 | Zymogenetics L L C | Frembringelse og rensning af IL-29 |
| CN101002942B (zh) * | 2007-01-08 | 2010-07-21 | 湖南大学 | 一种peg化脂质体纳米颗粒 |
| EP2296691A1 (en) * | 2008-06-05 | 2011-03-23 | ZymoGenetics, L.L.C. | Use of pegylated type iii interferons for the treatment of hepatitis c |
-
2012
- 2012-03-01 AU AU2012299423A patent/AU2012299423A1/en not_active Abandoned
- 2012-03-01 RU RU2014111179/10A patent/RU2014111179A/ru not_active Application Discontinuation
- 2012-03-01 JP JP2014527142A patent/JP2014525939A/ja not_active Withdrawn
- 2012-03-01 CA CA2846092A patent/CA2846092A1/en not_active Abandoned
- 2012-03-01 CN CN2012800033678A patent/CN103228792A/zh active Pending
- 2012-03-01 BR BR112014004302A patent/BR112014004302A2/pt not_active IP Right Cessation
- 2012-03-01 WO PCT/US2012/027317 patent/WO2013028233A1/en unknown
- 2012-03-01 EP EP12825651.8A patent/EP2748328A4/en not_active Withdrawn
-
2014
- 2014-02-14 ZA ZA2014/01159A patent/ZA201401159B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN103228792A (zh) | 2013-07-31 |
| BR112014004302A2 (pt) | 2017-06-20 |
| JP2014525939A (ja) | 2014-10-02 |
| EP2748328A1 (en) | 2014-07-02 |
| EP2748328A4 (en) | 2015-03-04 |
| AU2012299423A1 (en) | 2014-03-06 |
| CA2846092A1 (en) | 2013-02-28 |
| ZA201401159B (en) | 2015-04-29 |
| WO2013028233A1 (en) | 2013-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2014111179A (ru) | КОНЪЮГАТЫ ИНТЕРФЕРОНА λ1 И ПОЛИЭТИЛЕНГЛИКОЛЯ | |
| US10532086B2 (en) | Methods and compositions for modulating the immune system with arginase I | |
| RU2008126305A (ru) | Новый пептид | |
| US8454947B1 (en) | PEG-interferon lambda 1 conjugates | |
| JP2014525939A5 (enrdf_load_stackoverflow) | ||
| JP2011522834A5 (enrdf_load_stackoverflow) | ||
| JP2010505831A5 (enrdf_load_stackoverflow) | ||
| CN109467566B (zh) | 用于治疗和/或预防与肝炎病毒相关的疾病或病症的双二氮杂双环化合物 | |
| RU2010126598A (ru) | Применение человеческого антитела, способного нейтрализовать вирус гепатита в, для профилактики или лечения инфекции вирусом гепатита в | |
| KR102599942B1 (ko) | Hbv 및 hdv 감염의 조합 치료법 | |
| US20150202218A1 (en) | Broad Spectrum Inhibitors of the Post Proline Cleaving Enzymes for Treatment of Hepatitis C Virus Infections | |
| EP2030628A1 (en) | A peptide for preventing or treating liver damage and its derivant and the use | |
| MX2008014358A (es) | Conjugado de polietilenglicol-interferon alfa. | |
| RU2006101166A (ru) | Рекомбинантные антитела и композиции и способы их получения и использования | |
| RU2008125167A (ru) | Терапевтическое средство для ускоренного заживления кожи, содержащее в качестве активного ингредиента дезацил-грелин и его производные | |
| JP2006524704A (ja) | アルファチモシンペプチドによる呼吸器ウイルス感染の治療または予防 | |
| TW201010692A (en) | Pharmaceutical composition for treatment or prevention of hbv infection | |
| RU2597795C2 (ru) | Ингибитор скопления жидкости в полостях организма | |
| KR20250117319A (ko) | 미토콘드리아 기능 개선 펩타이드의 항암 용도 | |
| WO2016085279A2 (ko) | 세포 투과 펩타이드-면역조절제 접합체 및 이를 포함하는 면역질환 치료용 조성물 | |
| CN106132983A (zh) | 新型IFN‑β蛋白类似物 | |
| KR20240159721A (ko) | 지방산-펩타이드 접합체 | |
| RU2012109938A (ru) | Способ лечения вирусного гепатита с | |
| HK1262528A1 (en) | Diazabicyclo compounds for use in the treatment and/or prevention of diseases or conditions associated with hepatitis viruses | |
| HK1262528B (en) | Diazabicyclo compounds for use in the treatment and/or prevention of diseases or conditions associated with hepatitis viruses |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20160914 |